Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management

References

• Tucker MA, Goldstein AM. Melanoma etiology: where are we? Oncogene 2003; 22:3042-52; PMID:12789279; http://dx.doi.org/10.1038/sj.onc.1206444
   PubMed Web of Science ®Google Scholar
• Dodd AT, Morelli J, Mokrohisky ST, Asdigian N, Byers TE, Crane LA. Melanocytic nevi and sun exposure in a cohort of colorado children: anatomic distribution and site-specific sunburn. Cancer Epidemiol Biomarkers Prev 2007; 16:2136-43; PMID:17932362; http://dx.doi.org/10.1158/1055-9965.EPI-07-0453
   PubMed Web of Science ®Google Scholar
• Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999; 10:3245-51
   Google Scholar
• Quaglino P, Borgognoni L, Bottoni U, Calvieri S, Carli P, Catricalà C, Eibenschutz L, Manganoni A, Moretti S, Pellacani G, et al. Italian guidelines for staging and follow-up of stage I-I cutaneous melanoma patients. G Ital Dermatol Venereol 2007; 142:41-7
   Google Scholar
• Brogelli L, Reali UM, Moretti S, Urso C. The prognostic significance of histologic regression in cutaneous melanoma. Melanoma Res 1992; 2:87-91; PMID:1643435; http://dx.doi.org/10.1097/00008390-199207000-00002
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-16; PMID:10561265
   PubMed Web of Science ®Google Scholar
• Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6:S11-4; PMID:10685652
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperatie Oncology Group Trial EST1684. J Clin Oncol 1996; 14:7-17; PMID:8558223
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Onco 2000; 18:2444-58
   PubMed Web of Science ®Google Scholar
• Hoos RI, Korman AA, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010:533-46; PMID:21074069; http://dx.doi.org/10.1053/j.seminoncol.2010.09.015
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Drake CG, Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Canc Res 2011; 17:6958-62; http://dx.doi.org/10.1158/1078-0432.CCR-11-1595
   PubMed Web of Science ®Google Scholar
• Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P. A new member of the immunoglobulin superfamily–CTLA-4. Nature 1987; 328:267-70; PMID:3496540; http://dx.doi.org/10.1038/328267a0
   PubMed Web of Science ®Google Scholar
• Brunet JF, Denizot F, Golstein P. A differential molecular biology search for genes preferentially expressed in functional T lymphocytes: the CTLA genes. Immunol Rev 1988; 103:21-36; PMID:3134293; http://dx.doi.org/10.1111/j.1600-065X.1988.tb00747.x
   PubMed Web of Science ®Google Scholar
• Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009; 229:12-26; PMID:19426212; http://dx.doi.org/10.1111/j.1600-065X.2009.00770.x
   PubMed Web of Science ®Google Scholar
• Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004:336-47; PMID:15122199; http://dx.doi.org/10.1038/nri1349
   PubMed Web of Science ®Google Scholar
• Nirschl CJ, Drake CG. Molecular pathways: coexpression of immune checkpoint molecules: Signaling pathways and implications for cancer immunotherapy. Clin Canc Res 2013; 19:4917-24; http://dx.doi.org/10.1158/1078-0432.CCR-12-1972
   PubMed Web of Science ®Google Scholar
• Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S. CTLA-4 control over Foxp3+ regulatory T cell function. Science, 2008; 322:271-5; PMID:18845758; http://dx.doi.org/10.1126/science.1160062
   PubMed Web of Science ®Google Scholar
• Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, Brogdon JL. Activating Fcγreceptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med, 2013; 210:1685-93. Epub 2013 Jul 29; PMID:23897982; http://dx.doi.org/10.1084/jem.20130573
   PubMed Web of Science ®Google Scholar
• Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013; 1:32-42. Epub 2013 Apr 7; PMID:24777248; http://dx.doi.org/10.1158/2326-6066.CIR-13-0013
   PubMed Web of Science ®Google Scholar
• Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 26:2101695-710
   Google Scholar
• Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison PA. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009; 206:1717-25; PMID:19581407; http://dx.doi.org/10.1084/jem.20082492
   PubMed Web of Science ®Google Scholar
• FDA FDA. Approves New Treatment for a Type of Late-Stage Skin Cancer. Media Release. 25 Mar 2011. Available from URL: http://www.fda.gov
   Google Scholar
• Bristol-Myers Squibb Company. FDA Approves YERVOY(Tm) (ipilimumab) for the Treatment of Patients with Newly Diagnosed or Previously-Treated Unresectable or Metastatic Melanoma, the Deadliest Form of Skin Cancer. Media Release. 26 Mar 2011. Available from URL:http://www.bms.com
   Google Scholar
• Bristol-Myers Squibb Company. Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data and Double-Digit EPS Growth. Media Release. 22 Jul 2010. Available from URL: http://www.bms.com
   Google Scholar
• Dai D, Wu C, Parker SM, et al. Model-based evaluation of ipilimumab dosage regimen in patients with advanced melanoma. 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 9073, 30 May 2008. Available from http://www.asco.org
   Google Scholar
• Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T, Jr, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-64; PMID:20004617; http://dx.doi.org/10.1016/S1470-2045(09)70334-1
   PubMed Web of Science ®Google Scholar
• Small EJ, Tchekmedyian EN, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti- CTLA-4 in patients with hormone-refractory prostate cancer. Clin Canc Res 2007; 13:1810-15 Mar 15; http://dx.doi.org/10.1158/1078-0432.CCR-06-2318
   PubMed Web of Science ®Google Scholar
• Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, Habermann TM, Inwards DJ, Verma M, Yamada R, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Canc Res 2009; 15:6446-53; http://dx.doi.org/10.1158/1078-0432.CCR-09-1339
   PubMed Web of Science ®Google Scholar
• Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30:825-30; PMID:18049334; http://dx.doi.org/10.1097/CJI.0b013e318156e47e
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company. Controlled Phase 2 Study of Ipilimumab Shows Clinical Activity in Advanced Non-Small Cell Lung Cancer. Media Release 22 May 2010.Available from URL: http://www.bms.com
   Google Scholar
• Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412-20; PMID:19934295; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624
   PubMed Web of Science ®Google Scholar
• Young SE, Giuliano AE, Morton DL, Three decades of evolving treatment for melanoma: no improvement in survival? J Clin Oncol 2005; 23(Suppl.):abstr751
   Google Scholar
• Keler T, Halk E, Vitale L, O'Neill T, Blanset D, Lee S, Srinivasan M, Graziano RF, Davis T, Lonberg N, Korman A. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J Immunol 2003; 171:6251-9; PMID:14634142; http://dx.doi.org/10.4049/jimmunol.171.11.6251
   PubMed Web of Science ®Google Scholar
• Yang YF, Zou JP, Mu J, Wijesuriya R, Ono S, Walunas T, Bluestone J, Fujiwara H, Hamaoka T. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res 1997; 57:4036-41; PMID:9307290
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP, Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271:1734-6; PMID:8596936; http://dx.doi.org/10.1126/science.271.5256.1734
   PubMed Web of Science ®Google Scholar
• Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal infl ammation. J Exp Med 2000; 192:295-302; PMID:10899916; http://dx.doi.org/10.1084/jem.192.2.295
   PubMed Web of Science ®Google Scholar
• Perrin PJ, Maldonado JH, Davis TA, June CH, Racke MK. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol 1996; 157:1333-6; PMID:8759711
   PubMed Web of Science ®Google Scholar
• Luhder F, Hoglund P, Allison JP, Benoist C, Mathis D. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med 1998; 187:427-32; PMID:9449722; http://dx.doi.org/10.1084/jem.187.3.427
   PubMed Web of Science ®Google Scholar
• Mokyr MB, Kalinichenko T, Gorelik L, Bluestone JA. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res 1998; 58:5301-4; PMID:9850053
   PubMed Web of Science ®Google Scholar
• Chambers CA, Kuhns MS, Egen JG, Allison JP, CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001; 19:565-94; PMID:11244047; http://dx.doi.org/10.1146/annurev.immunol.19.1.565
   PubMed Web of Science ®Google Scholar
• Ariyan C, Salvalaggio P, Fecteau S, Deng S, Rogozinski L, Mandelbrot D, Sharpe A, Sayegh MH, Basadonna GP, Rothstein DM. Cutting edge: transplantation tolerance through enhanced CTLA-4 expression. J Immunol 2003; 171:5673-7; PMID:14634073; http://dx.doi.org/10.4049/jimmunol.171.11.5673
   PubMed Web of Science ®Google Scholar
• Greenwald RJ, Latchman YE, Sharpe AH, Negative co-receptors on lymphocytes. Curr Opin immunol 2002; 14:391-6; PMID:11973140; http://dx.doi.org/10.1016/S0952-7915(02)00341-2
   PubMed Web of Science ®Google Scholar
• van Elsas A, Hurwitz AA, Allison JP, Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumours accompanied by autoimmune depigmentation. J Exp Med 1999; 190:355-66; PMID:10430624; http://dx.doi.org/10.1084/jem.190.3.355
   PubMed Web of Science ®Google Scholar
• Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patiño JA, Perales MA, Mortazavi F, Bacich D, Heston W, Latouche JB, et al. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self-antigens in animal and cellular model systems. Vaccine 2004; 22:1700-8; PMID:15068853; http://dx.doi.org/10.1016/j.vaccine.2003.10.048
   PubMed Web of Science ®Google Scholar
• Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic Tlymphocyte antigen-4. J Clin Oncol 2005; 23:6043-53; PMID:16087944; http://dx.doi.org/10.1200/JCO.2005.06.205
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ et al., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003; 100:8372-7; PMID:12826605; http://dx.doi.org/10.1073/pnas.1533209100
   PubMed Web of Science ®Google Scholar
• Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh El. Phase I/II study of ipilimumab or patients with metastatic melanoma. J Clin Oncol 2008; 26:5950-6; PMID:19018089; http://dx.doi.org/10.1200/JCO.2008.16.1927
   PubMed Web of Science ®Google Scholar
• Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, et al. Tumor regression and autoimmunityin patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann Surg Oncol 2005; 12:1005-16; PMID:16283570; http://dx.doi.org/10.1245/ASO.2005.03.536
   PubMed Web of Science ®Google Scholar
• O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21:1712-7. Epub 2010 Feb 10; http://dx.doi.org/10.1093/annonc/mdq013
   PubMed Web of Science ®Google Scholar
• Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 2011; 29:489-98; PMID:20082117; http://dx.doi.org/10.1007/s10637-009-9376-8
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. J Clin Oncol 2015; 33:1889-94. Epub 2015 Feb 9; PMID:25667295; http://dx.doi.org/10.1200/JCO.2014.56.2736
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23. Epub 2010 Jun 5; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S. MDX010-20 investigators. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 2013; 19:2232-9. Epub 2013 Feb 26
   PubMed Web of Science ®Google Scholar
• Ascierto P, Simeone E, Chiarion Sileni V, Pigozzo J, Maio M, Altomonte M, Del Vecchio M, Di Guardo L, Marchetti P, Ridolfi R, et al. Clinical experience with Ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 2014; 12:116; PMID:24885479; http://dx.doi.org/10.1186/1479-5876-12-116
   PubMed Web of Science ®Google Scholar
• Kelderman S, Heemskerk B, van Tinteren H, van den Brom RR, Hospers GA, van den Eertwegh AJ, Kapiteijn EW, de Groot JW, Soetekouw P, Jansen RL, et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Canc Immunol Immunother 2014; 63:449-58. Epub 2014 Mar 8; PMID:24609989
   PubMed Web of Science ®Google Scholar
• Berrocal A, Arance A, Lopez Martin JA, Soriano V, Muñoz E, Alonso L, Espinosa E, Lopez Criado P, Valdivia J, Martin Algarra S, et al. Spanish Melanoma Group. Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program. Melanoma Res 2014; 24:577-83; PMID:25046550; http://dx.doi.org/10.1097/CMR.0000000000000108
   PubMed Web of Science ®Google Scholar
• Ahmad S, Qian W, Ellis S, Mason E, Khattak MA, Gupta A, Shaw H, Quinton A, Kovarikova J, Thillai K, et al. Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Res 2015; 25:432-42; http://dx.doi.org/10.1097/CMR.0000000000000185
   PubMed Web of Science ®Google Scholar
• Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase2 trial. Lancet Oncol 2012; 13:459-65. Epub 2012 Mar 27; PMID:22456429; http://dx.doi.org/10.1016/S1470-2045(12)70090-6
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 2012; 13:879-86. Epub 2012 Aug 13; PMID:22894884; http://dx.doi.org/10.1016/S1470-2045(12)70324-8
   PubMed Web of Science ®Google Scholar
• Weber JS1, Amin A, Minor D, Siegel J, Berman D, O'Day SJ. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 2011; 21:530-4; PMID:22051508; http://dx.doi.org/10.1097/CMR.0b013e32834d3d88
   PubMed Web of Science ®Google Scholar
• Konstantinou MP, Dutriaux C, Gaudy-Marqueste C, Mortier L, Bedane C, Girard C, Thellier S, Jouary T, Grob JJ, Richard MA, et al. Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients. Acta Derm Venereol 2014; 94:45-9; PMID:23824275; http://dx.doi.org/10.2340/00015555-1654
   PubMed Web of Science ®Google Scholar
• Della Vittoria, Scarpati G, Fusciello C, Perri F, Sabbatino F, Ferrone S Carlomagno C, Pepe S. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther 2014; 19:203-9. eCollection 2014; http://dx.doi.org/10.2147/OTT.S57335
   Web of Science ®Google Scholar
• Wolchok JD, Weber JS, Hamid O, Lebbé C, Maio M, Schadendorf D, de Pril V, Heller K, Chen TT, Ibrahim R. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun 2010; 20(10):9
   Google Scholar
• Lacouture ME, Wolchok JD, Yosipovitch G, Kähler KC, Busam KJ, Hauschild A. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol 2014; 71:161-9. Epub 2014 Apr 24; PMID:24767731; http://dx.doi.org/10.1016/j.jaad.2014.02.035
   PubMed Web of Science ®Google Scholar
• Weber J, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with Ipilimumab. J Clin Oncol 2012; 30:2691-7. Epub 2012 May 21; PMID:22614989; http://dx.doi.org/10.1200/JCO.2012.41.6750
   PubMed Web of Science ®Google Scholar
• Postow MA, Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015; 35:76-83; http://dx.doi.org/10.14694/EdBook_AM.2015.35.76
   Google Scholar
• Horvat TZ, Adel NG, Dang T, Momtaz P, Postow MA, Callahan MK, Carvajal MD, Dickson MA, D'Angelo SP, Woo KM, et al. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015; 33:1-6. Epub 2015 Aug 17; PMID:25332246; http://dx.doi.org/10.1200/JCO.2015.60.8448
   PubMed Web of Science ®Google Scholar
• Bostwick AD, Salama AK, Hanks AB. Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J ImmunoTher Canc 2015, 3:19-26; http://dx.doi.org/10.1186/s40425-015-0064-2
   PubMedGoogle Scholar
• Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T lymphocyte- associated antigen 4. J Clin Oncol 2006; 24:2283-9; PMID:16710025; http://dx.doi.org/10.1200/JCO.2005.04.5716
   PubMed Web of Science ®Google Scholar
• Gupta A, De Felice KM, Loftus EV, Khanna S, Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 2015; 42:406-17. Epub 2015 Jun 15; PMID:26079306; http://dx.doi.org/10.1111/apt.13281
   PubMed Web of Science ®Google Scholar
• Min L, Vaidya A, Becker C, Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. Endocr Pract 2012; 18:351-5; PMID:22138079; http://dx.doi.org/10.4158/EP11273.OR
   PubMed Web of Science ®Google Scholar
• Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005; 28:593-8; PMID: 16224277; PMID:16224277; http://dx.doi.org/10.1097/01.cji.0000178913.41256.06
   PubMed Web of Science ®Google Scholar
• Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, Nachtigall L. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 2014; 99:4078-85. Epub 2014 Jul 31; PMID:25078147; http://dx.doi.org/10.1210/jc.2014-2306
   PubMed Web of Science ®Google Scholar
• Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014; 21:371-81. Print 2014 Apr; PMID:24610577; http://dx.doi.org/10.1530/ERC-13-0499
   PubMed Web of Science ®Google Scholar
• Min L, Hodi FS, Giobbie-Hurder A, Ott PA, Luke JJ, Donahue H, Davis M, Carroll RS, Kaiser UB. Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab- Related Hypophysitis: A Retrospective Cohort Study. Clin Cancer Res 2015; 21:749-55. Epub 2014 Dec 23; PMID:25538262; http://dx.doi.org/10.1158/1078-0432.CCR-14-2353
   PubMed Web of Science ®Google Scholar
• Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, et al. A randomized, double-blind, placebo-controlled, phase II Study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15:5591-8. Epub 2009 Aug 11; PMID:19671877; http://dx.doi.org/10.1158/1078-0432.CCR-09-1024
   PubMed Web of Science ®Google Scholar
• Araujo PB, Coelho MC, Arruda M, Gadelha MR, Neto LV. Ipilimumab-induced hypophysitis: review of the literature. J Endocrinol Invest 2015 May 10; 38(11):1159-66. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL- associated antigen-4 blockade. Clin Cancer Res 2007; 13:6681-8; PMID:17982122; http://dx.doi.org/10.1158/1078-0432.CCR-07-0187
   PubMed Web of Science ®Google Scholar
• De Felice KM, Gupta A, Rakshit S, Khanna S, Kottschade LA, Finnes HD, Papadakis KA, Loftus EV, Jr, Raffals LE, Markovic SN. Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res 2015; 25:321-7; PMID:25933207; http://dx.doi.org/10.1097/CMR.0000000000000165
   PubMed Web of Science ®Google Scholar
• Maker, AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006; 29:455-63; PMID:16799341; http://dx.doi.org/10.1097/01.cji.0000208259.73167.58
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Melanoma Vol. 3.2014. Available at http://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf (accessed 10 December 2013)
   Google Scholar
• Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-75. Epub 2010 Jun 1; PMID:20516446; http://dx.doi.org/10.1200/JCO.2009.26.7609
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30. Epub Mar 3; PMID:24590637; http://dx.doi.org/10.1200/JCO.2013.53.0105
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44. Epub 2013 Jun 2; PMID:23724846; http://dx.doi.org/10.1056/NEJMoa1305133
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, et al. Anti-programmed-death- receptor-1 treatment with pembrolizumab in ipilimumab- refractory advanced melanoma: a randomised dose- comparison cohort of a phase 1 trial. Lancet 2014; 384:1109-17. Epub 2014 Jul 15; PMID:25034862; http://dx.doi.org/10.1016/S0140-6736(14)60958-2
   PubMed Web of Science ®Google Scholar
• Ganghadar TC, Vonderheide RH. Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol 2014 Feb; 11(2):91-9; Epub 2014 Jan 21; http://dx.doi.org/10.1038/nrclinonc.2013.245
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33. Epub 2013 Jun 2; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23-34. Epub 2015 May 31; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372:200 6-17. Epub 2015 Apr 20; http://dx.doi.org/10.1056/NEJMoa1414428
   Web of Science ®Google Scholar
• Ascierto PA, Marincola FM, Atkins M. What's new in melanoma? Combination! J Transl Med 2015; 13:213; PMID:26141621; http://dx.doi.org/10.1186/s12967-015-0582-1
   PubMed Web of Science ®Google Scholar
• Puzanov I, Milhem MM, Andtbacka RHI, Minor DR, Hamid O, Li A, et al. Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previ- ously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol 2015; 33 (suppl; abstr 9063)
   Web of Science ®Google Scholar
• Puzanov I, Callahan MK, Linette GP, Patel SP, Luke JL, Sosman JA, et al. Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). J Clin Oncol 2014; 32:5 (suppl; abstr 2511); PMID:24590637
   PubMed Web of Science ®Google Scholar
• Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368:1365-6; PMID:23550685; http://dx.doi.org/10.1056/NEJMc1302338
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366:925-31; PMID:22397654; http://dx.doi.org/10.1056/NEJMoa1112824
   PubMed Web of Science ®Google Scholar
• Mathew M, Tam M, Ott PA, Pavlick AC, Rush SC, DonahueBR, Golfinos JG, Parker EC, Huang PP, Narayana A. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 2013; 23:191-5; PMID:23462208; http://dx.doi.org/10.1097/CMR.0b013e32835f3d90
   PubMed Web of Science ®Google Scholar
• Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 2012; 117:227-3. Epub 2012 Jun 15; PMID:22702482; http://dx.doi.org/10.3171/2012.5.JNS111929
   PubMed Web of Science ®Google Scholar
• Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2013; 2:899-906. Epub 2013 Oct 10; PMID:24403263; http://dx.doi.org/10.1002/cam4.140
   PubMed Web of Science ®Google Scholar
• Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, Lee NY, Wolchok JD. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res 2013; 1:92-8. Epub 2013 Jul 25; PMID:24777500; http://dx.doi.org/10.1158/2326-6066.CIR-13-0082
   PubMed Web of Science ®Google Scholar
• Mir LM, Gehl J, Sersa G, Collins CG, Garbay J-R, Billard V, Geertsen PF, Rudolf Z, O'Sullivan GC, Marty M. Standard operating procedures of the electro- chemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. EJC Sup-plements 2006; 4:14-25; http://dx.doi.org/10.1016/j.ejcsup.2006.08.003
   Web of Science ®Google Scholar
• Mozzillo N, Simeone E, Benedetto L, Curvietto M, Giannarelli D, Gentilcore G, Camerlingo R, Capone M, Madonna G, Festino L, et al. Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. Onco Immunol 2015; 4(6):e1008842; June; http://dx.doi.org/10.1080/2162402X.2015.1008842
   Google Scholar
• Brizio M, Fava P, Astrua C, Cavaliere G, Savoia P. Complete regression of melanoma skin metastases after electrochemotherapy plus ipilimumab treatment: an unusual clinical presentation. Eur J Dermatol 2015; 25(3):271-2. Jun 9 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, et al. Ipilimumab in combination with carboplatin plus paclitaxel as first-line treatment in stage IIIB/IV NSCLC results from a randomised, double-blind, multicenter phase II study. J Clin Oncol 2012; 30:2046-54; PMID:22547592; http://dx.doi.org/10.1200/JCO.2011.38.4032
   PubMed Web of Science ®Google Scholar
• Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Lu H, Cuillerot JM, Lynch TJ. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013; 24:75-83
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Addeo R, Cartenì G, Daniele B, De Laurentis M, Ianniello GP, Morabito A, Palmieri G, Pepe S, Perrone F, et al. The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. J Translat Med 2014; 12:291-306 http://www.translational-medicine.com/content/12/1/291; http://dx.doi.org/10.1186/s12967-014-0291-1
   PubMed Web of Science ®Google Scholar